SCHEMBL29778396

SCHEMBL29778396

CC(=O)Nc1cccc(Cn2ccc3cc(-c4c[nH]nc4C)ccc3c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.48
MKNK2 Q9HBH9 2/20 0.48
LMNA P02545 3/20 0.45
ROCK2 O75116 1/20 0.45
ROCK1 Q13464 1/20 0.45
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
PARP1 P09874 1/20 0.39
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
MAPT P10636 3/20 0.39
KDR P35968 1/20 0.37
PTGER3 P43115 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24617391 1.00 MKNK1 (0.48) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL29778661 0.90 MKNK1 (0.47) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL24617332 0.90 MKNK1 (0.47) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL29135999 0.89 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL29778544 0.89 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL29778606 0.88 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL24617389 0.88 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL24617607 0.85 ROCK2 (0.49) LMNAROCK2ROCK1MEN1KMT2A
SCHEMBL24617705 0.84 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1
SCHEMBL29778702 0.84 MKNK1 (0.46) MKNK1MKNK2LMNAROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 MKNK1 101/4885MKNK2 50/4885LMNA 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.